NASDAQ · RYTM

Rhythm Pharmaceuticals, Inc.

Healthcare · Biotechnology

$99.02▲ 1.03% ($1.01)at close

As of 4:00 PM ET

52-week

$74.50$122.20

Market cap

$6.79B

P/E

No multiple

What the market price implies · Reverse DCF

To support a price of $99.02, this model requires revenue to grow by 65.03%/yr over the next 10 years, compounded annually.

Historical revenue grew by 178.51%/yr over the past 4 years. The required annual growth rate is 113.47 percentage points lower.

Selected forecast · Base scenario

19.61%/yr · actual 10-year annualized revenue growth

Year 1 growth: 40%

Market-implied · Base operating assumptions + edited margins

65.03%/yr · flat 10-year annualized revenue growth

Reverse DCF solves revenue growth itself using Base operating assumptions and your edited margins. Changing forecast growth alone does not change the implied rate. This is a model-implied requirement, not an analyst forecast.

Valuation

Recommended · Revenue & margin DCF

Price used

$99.02

Estimated value / share

$6.11

Base scenario

This estimate is 93.83% below the price used.

USD · TTM ending 2026-06-30

Year 1 growth 40% · Ending margin 0% · Discount rate 15.77%

Assumption scenarios, not statistical confidence intervals.

Method, dates & sources

Estimated from future revenue, operating margins, and the investment needed to support them.

Price timestamp: Sep 17, 2026, 8:00 PM UTC
Financial statement period: TTM ending 2026-06-30
Data refreshed: Sep 18, 2026, 2:30 AM UTC · provider

Why this method?

There is not a stable run of positive FCFF to anchor a direct cash-flow CAGR, so the model should start from revenue and margin assumptions instead.

Is FCFF positive and has it been for 3+ consecutive years? Latest FCFF is not positive.

Price vs Fundamentals

Why The Stock Is Moving

Mixed / unclearLow confidence

1Y Price: 3.04%Revenue (TTM): 53.51%FCF (TTM): -39.7%P/S: 47th pct

What changed

The stock rose 3.04% over the last year. Revenue grew 53.51% over the trailing twelve months. Operating margin moved from -113.53% to -83.62%. Free cash flow declined 39.7% over the trailing twelve months.

What the market seems to be pricing

The stock has moved higher against modestly improving underlying metrics. The operating data does not yet tell a clear story — the move may reflect sentiment, sector rotation, or macro factors rather than company-specific earnings power.

What would invalidate this read

Operating margin currently stands at -83.62%. A decisive move in revenue — currently up 53.51% — would be the clearest signal to resolve the ambiguity.

Performance

Return analysis

Company profile

Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company with commercial products, dedicated to the discovery, development, and market launch of therapies addressing rare genetic conditions that cause obesity.

CEODavid Meeker

SectorHealthcare

IndustryBiotechnology

Employees414

IPO dateOct 9, 2017

https://www.rhythmtx.com

Market multiples

Forward P/E—

EV/EBITDA-39.66

Enterprise value$6.91B

Stock splits

No stock splits recorded for this ticker.

Profitability & growth

Revenue growth46.91%

Gross margin (FY2025)89.73%0.0ppvs FY2024

Operating margin (FY2025)-101.19%▲102.8ppvs FY2024

ROE-117.04%▼26.6ppvs FY2025

Analyst consensus

RatingBuy

Target price$143.83▲45.25%

Buy

Hold

Sell

Analyst ratings tend to be lagging indicators. Use as one signal among many.

Earnings

Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.

Next report

Nov 3, 2026

Q4 FY26 · EPS est -$0.72 · Revenue est $84.52M

View